山东鲁抗医药股份有限公司关于控股子公司获得药品注册证书的公告

Group 1 - The company has received a drug registration certificate for Sildenafil Hydrochloride Tablets, classified as a generic drug under category 4, indicating it has passed the quality and efficacy consistency evaluation [1][2] - The drug is a phosphodiesterase type 5 (PDE5) inhibitor, used to treat male erectile dysfunction by enhancing blood flow to the penis [2] - There are currently 14 production approvals for Sildenafil Hydrochloride Tablets in China, with 11 companies having passed the quality and efficacy evaluation [2] Group 2 - The company has invested approximately RMB 6.8 million in the research and development of this drug [3] - The approval of the drug is expected to optimize the company's product structure and maintain stable production capacity to meet market demand, positively impacting future operations [4] - The domestic sales of Sildenafil Hydrochloride Tablets are projected to be around RMB 53.12 million in 2024 [2]